Autor: |
Nolan, Annelise, McGowan, Melissa, Von Stein, Lauren, Ross, Adrienne, Kaur, Manjit, Pesavento, Todd, Singh, Priyamvada |
Předmět: |
|
Zdroj: |
Clinical Transplantation; Jan2024, Vol. 38 Issue 1, p1-4, 4p |
Abstrakt: |
Background: With the availability of vaccines against SARS‐COV‐2, recommendations for vaccination of transplant candidates are widespread. At our institution, patients may receive liver transplant (LTx) regardless of vaccine status. The purpose of this study is to compare post‐LTx outcomes between vaccinated (VAX) and unvaccinated (UNVAX) LTx recipients. Methods: This is a retrospective, single‐center study of LTx from January 1, 2021–March 30, 2022. The primary outcome is incidence of post‐LTx COVID‐19. Secondary outcomes include graft function, mortality, graft loss, and COVID‐19 treatment. Results: One hundred and seventy‐seven LTx recipients were included, 57% [101/177] VAX and 43% [76/177] UNVAX. Baseline characteristics were similar between groups. Overall, 28 (36.8%) UNVAX and 34 (33.7%) VAX tested COVID‐19 positive during the study period (p =.193) at a mean of 312.6 [255.4–369.8] days for UNVAX versus 254.6 [215.2–293.9] days for VAX (p =.084). COVID‐19 treatment was administered in 15 (53.6%) of the UNVAX compared to 22 (64.7%) in the VAX (p =.374), although eight (28.6%) of UNVAX required hospital admission for treatment compared with two (5.9%) of VAX (p =.016). There were no statistically significant differences in death, and no COVID‐19 related death or graft loss. There were no statistically significant differences in liver function tests at 3‐ and 12‐months post LTx. Conclusion: In a series with a large percentage of UNVAX patients, LTx appears to be safe, with no difference in the rate of COVID‐19 or transplant‐related outcomes compared to VAX. While we encourage vaccination to prevent severe COVID, based on our results, vaccine status should not be reason to deny lifesaving transplant. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|